epoetin alfa

Also found in: Medical, Wikipedia.

e·po·e·tin al·fa

 (ĭ-pō′ĭ-tĭn ăl′fə)
A recombinant preparation of human erythropoietin used to treat some forms of anemia.

[e(rythro)po(i)etin + alteration of alpha.]
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.

epoetin alfa

n epoetina alfa
English-Spanish/Spanish-English Medical Dictionary Copyright © 2006 by The McGraw-Hill Companies, Inc. All rights reserved.
Mentioned in ?
References in periodicals archive ?
SAN ANTONIO -- Epoetin alfa shows considerable promise for prevention of the cognitive dysfunction associated with adjuvant chemotherapy in breast cancer patients, Dr.
The company expects combined sales of EPOGEN(R) (Epoetin alfa), Amgen's anemia therapy for patients on dialysis, and Aranesp(TM) (darbepoetin alfa), its next-generation anemia treatment, to grow in the low 20 percent range over the prior year.
New improved products, especially stem cell factor (SCF) and novel erythropoietin-stimulating protein (NESP), will add the strongest momentum to growth and partially offset the effect of tighter Medicare price controls over the use of epoetin alfa in dialysis.
These patients were randomised to secure either roxadustat or epoetin alfa in the trial.
Previously noted side effects of epoetin alfa include high blood pressure, joint pain, muscle spasm, fever, dizziness, blood vessel blockage, and respiratory infection, the FDA said.
Results of the first human trials of rHuEPO were published in 1986-1987 (Eschbach, Egrie, Downing, Browne, & Adamson, 1987; Winearls et al., 1986), paving the way for the clinical introduction of the first rHuEPO, epoetin alfa (Epogen[R], Amgen; also marketed under the brand name Procrit[R] by Johnson & Johnson), in the United States in 1989 (Demirjian & Nurko, 2008; Goldsmith, 2010).
In Europe, the innovator product, Eprex (Epoetin alfa, Janssen-Ortho Inc, Canada), has been available for several years.
The medication guide is part of a Risk Evaluation and Mitigation Strategy (REMS) focusing specifically on erythropoiesis-stimulating agents (ESAs), including Procrit (epoetin alfa), Aranesp (darbepoetin alfa) and Epogen (epoetin alfa).
The second feature article is entitled "Reduced drug costs from switching hemodialysis patients from epoetin alfa in multidose vials to pre-filled syringes." This research article was written by Lori Wazny, Colette Raymond and their pharmacist colleagues in the Manitoba Renal Program.
Other approved indications for ESAs include the treatment of anemia associated with chronic renal failure; epoetin alfa has been approved for use with zidovudine therapy in patients who have AIDS and for presurgical administration to reduce perioperative transfusion requirements.